Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: Analysis from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial

Ran Kornowski, Roxana Mehran, George Dangas, Eugenia Nikolsky, Abid Assali, Bimmer E. Claessen, Bernard J. Gersh, S. Chiu Wong, Bernhard Witzenbichler, Giulio Guagliumi, Dariusz Dudek, Martin Fahy, Alexandra J. Lansky, Gregg W. Stone

Research output: Contribution to journalArticlepeer-review

229 Scopus citations

Abstract

Objectives: The purpose of this study was to compare a one-time primary percutaneous coronary intervention (PCI) of the culprit and nonculprit lesions with PCI of only the culprit lesion and staged nonculprit PCI at a later date in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease. Background: In patients with STEMI and multivessel disease, it is unknown whether it is safe or even desirable to also treat the nonculprit vessel during the primary PCI procedure. Methods: In the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial, 668 of the 3,602 STEMI patients enrolled (18.5%) underwent PCI of culprit and nonculprit lesions for multivessel disease. Patients were categorized into a single PCI strategy (n = 275) versus staged PCI (n = 393). The endpoints analyzed included the 1-year rates of major adverse cardiovascular events and its components, death, reinfarction, target-vessel revascularization for ischemia, and stroke. Results: Single versus staged PCI was associated with higher 1-year mortality (9.2% vs. 2.3%; hazard ratio [HR]: 4.1, 95% confidence interval [CI]: 1.93 to 8.86, p < 0.0001), cardiac mortality (6.2% vs. 2.0%; HR: 3.14, 95% CI: 1.35 to 7.27, p = 0.005), definite/probable stent thrombosis (5.7% vs. 2.3%; HR: 2.49, 95% CI: 1.09 to 5.70, p = 0.02), and a trend toward greater major adverse cardiovascular events (18.1% vs. 13.4%; HR: 1.42, 95% CI: 0.96 to 2.1, p = 0.08). The mortality advantage favoring staged PCI was maintained in a subgroup of patients undergoing truly elective multivessel PCI. Also, the staged PCI strategy was independently associated with lower all-cause mortality at 30 days and at 1 year. Conclusions: A deferred angioplasty strategy of nonculprit lesions should remain the standard approach in patients with STEMI undergoing primary PCI, as multivessel PCI may be associated with a greater hazard for mortality and stent thrombosis. (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI]; NCT00433966)

Original languageEnglish
Pages (from-to)704-711
Number of pages8
JournalJournal of the American College of Cardiology
Volume58
Issue number7
DOIs
StatePublished - 9 Aug 2011

Keywords

  • angioplasty
  • coronary artery disease
  • myocardial infarction
  • stenting

Fingerprint

Dive into the research topics of 'Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: Analysis from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial'. Together they form a unique fingerprint.

Cite this